Amgen Articles
HGS licenses immuno-cancer gene to Amgen
16 January 2006
Stock Commentary - New York week to Jan 9
9 January 2006
Amgen announces $5B stock buy-back
19 December 2005
US FDA issues revised safety warning on Epogen, Aranesp and Procrit
12 December 2005
Galapagos extends deal with Amgen through 2006
12 December 2005
Stock Commentary - New York week to Dec 5
12 December 2005
Amgen anticipates rise in its Spanish sales
12 December 2005
Appointments at Nabi Pharma
19 September 2005
Kirin to boost R&D activity in USA
19 September 2005
FDA licenses to Amgen production facilities
12 September 2005
Phyllis Piano joins Amgen as VP corporate communications
12 September 2005
US FDA advisers urge appro of B-MS' Orencia
12 September 2005
Amgen initiates Ph III Aranesp study in HF
12 September 2005
Xoma recruits Alan Solinger as VP, clinical immunology
15 August 2005
Amgen's Kepivance gets nod from CHMP
8 August 2005
Stock Commentary - New York
1 August 2005
Enbrel drives Wyeht's 2nd-qtr sales
1 August 2005
Stock Commentary - New York
18 July 2005
Amgen's Aranesp gives 77% response in MDS
18 July 2005
Key appointments at Pharming NV
4 July 2005
New French biotech fund established
27 June 2005
FDA OKs additional indication for Enbrel
6 June 2005
Jim Daly promoted at Amgen
23 May 2005
Amgen submits sBLA for Aranesp
16 May 2005
Amgen/Abigenix' panitumumab enters Ph III
16 May 2005
Stock Commentary - New York
28 April 2005
Amgen posts 26% EPS hike, raises forecast
25 April 2005
UK guide for industry on Rx access in DCs
4 April 2005
Sweden's Biovitrum acquires Cambridge Biotechnology
28 March 2005
IMS: 2004 world Rx sales growth slowest in six yrs
14 March 2005
NPS/Ventiv create new sales force for Kineret
14 March 2005
Enbrel improves psoriasis symptoms, study confirms
28 February 2005
John Verniero to head Amgen Japan
28 February 2005
Amgen aborts PD drug clinical development
21 February 2005
SAFE biopharma digital identity standard move
21 February 2005
Hitch for Pennsylvania drug pricing suit
14 February 2005
Fen-phem charges gouge Wyeth results
7 February 2005
New product launches in 2004
31 January 2005
Highlights of pharmaceutical mergers and acquisitions in 2004
24 January 2005
Amgen adds safety warning to Aranesp
24 January 2005
Biogenerics to command more than $12B by 2010
17 January 2005
Preclinical program for RhuDex nearing completion
10 January 2005
NPS completes $175M offering backed by Sensipar royalties
10 January 2005
FDA clears Amgen's Kepivance
20 December 2004
Amgen announces $5B stock repurchase
13 December 2004
Stock Commentary - New York
13 December 2004
FDA fast-track for Amgen drugs
13 December 2004
Amgen prices $2B notes offer
22 November 2004
Amgen forms capital venture unit to help emerging biotechs
22 November 2004
Is greater commercialization of research just a pipe-dream? - by David Tubby of Marks & Clerk
15 November 2004
US drug market CAGR "set to slow to 9.7%"
15 November 2004
Amgen's Mimpara cleared in EU
8 November 2004
Nuvelo gains rights to alfimeprase from Amgen
8 November 2004
Genmab's nine-month income and loss widen
8 November 2004
TKT prevails in UK epoietin patent case
1 November 2004
New data for Amgen/Wyeth's Enbrel at ACR
25 October 2004
Rolf Hoffmann joins Amgen as senior VP, European operations
25 October 2004
Promising new data for Amgen's AMG-162
11 October 2004
Enbrel cleared for psoriasis in EU
11 October 2004
Expanded US label for Amgen/Wyeth's Enbrel
4 October 2004
Amgen appoints Arvind Sood VP, investor relations
27 September 2004
Kevin Young joins Gilead as exec VP, commercial operations
27 September 2004
Aranesp OKed for extended dosing in EU
27 September 2004
Immunomedics sees full-year loss leap 184%
20 September 2004
World dermatology mkt forecast to grow 8%/year through 2008
13 September 2004
Amgen completes Tularik acquisition
23 August 2004
Abgenix to receive milestone payment from Amgen
23 August 2004
Theresa Gerrard joins AustCancer
16 August 2004
Phase III studies for Amgen's AMG 162 underway
16 August 2004
NPS to promote Amgen's Kineret
16 August 2004
Genmab's 1st-half loss rockets 118%
16 August 2004
Aranesp on track for extended dosing in EU
16 August 2004
Amgen's 2nd-qtr 2004 EPS jumps 27%
9 August 2004
CHMP recommends Enbrel for psoriasis
9 August 2004
Amgen's Mimpara gets OK from CHMP
9 August 2004
Wyeth's 2nd-qtr profit slips, but sales climb
26 July 2004
Appointments at Amgen
19 July 2004
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
